The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ...

Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight loss — a major blow to the Indianapolis pharmaceutical company.

Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.